Health ❯Healthcare ❯Regulatory Affairs ❯European Medicines Agency

Drug Approval Process

Leqembi Approved by European Regulators for Early-Stage Alzheimer's Treatment

The decision overturns an initial rejection, confirming the drug's efficacy in slowing cognitive decline while addressing safety concerns.

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

EU Regulator Denies Approval for Alzheimer's Drug Lecanemab